Neurogene Inc. announced on June 29, 2026, positive, updated clinical data from its Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. The company will host a conference call and webcast to discuss the results. Neurogene Inc. is a biotechnology company focused on developing gene therapies for neurodevelopmental disorders.
